Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
about
Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a reviewHepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and preventionHepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion.Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC StudyTreatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug TherapyHCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatmentTreatment outcomes of treatment-naïve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohortsDrug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care CascadeConceptualizing Care Continua: Lessons from HIV, Hepatitis C Virus, Tuberculosis and Implications for the Development of Improved Care and Prevention Continua.Reinventing HCV Treatment: Past and Future Perspectives.Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era.Hepatitis C treatment experiences and decision making among patients living with HIV infection.The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic populationThe impact of HIV and high-risk behaviours on the wives of married men who have sex with men and injection drug users: implications for HIV preventionEngaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.Changes in blood-borne infection risk among injection drug users.Human immunodeficiency virus-related microbial translocation and progression of hepatitis C.Hepatitis infection in the treatment of opioid dependence and abuse.Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.Uptake and Acceptability of Information and Communication Technology in a Community-Based Cohort of People Who Inject Drugs: Implications for Mobile Health Interventions.Quality of hepatitis C care at an urban tertiary care medical center.Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control studyHIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.Current management of hepatitis C virus infection in patients with HIV co-infectionBreaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levelsNon-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health centerInteraction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV.Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapyManagement of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysisHazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort.Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse.Management of hepatic complications in HIV-infected persons.Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening.Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.Limited uptake of hepatitis C treatment among injection drug users
P2860
Q27010548-A8E7E097-0CB4-409A-A60B-99A713B1D650Q27014761-7082CF76-7A12-46D2-8769-FE1EA28742AAQ27321791-B9E6E8FD-E47A-4CFD-A82E-1DB3A97D250FQ27491349-50938B33-6F1C-42AE-B636-F785DE15A8EEQ28073100-86323C00-96B8-41A2-A364-243693D69895Q28265090-CC629888-7EA6-423B-99F7-C16E03508D6FQ28485972-AE6A836C-4278-44EC-A796-066CEAAF730FQ28547529-6477CC51-629E-4896-AE98-4FD172508D45Q30238798-7E2AB4C4-B2F8-498F-9BBA-44BBC87721B2Q30241881-244BA8D1-41E2-4BFC-9E50-7A9EA876490AQ33629538-DF104471-3470-49D4-AA43-AB3B5DB7F185Q33636377-5F7E1FD6-DC9A-491C-91F0-D88C3C70BC47Q33710740-9A667B8B-4CFF-4AD2-B3D0-D9DCD7A04D8DQ33810835-0CE954E8-B1BF-4806-A051-5E0A8DFAFBCEQ33935693-61FF5B3D-1D59-4D08-9E4D-C16046C2E851Q34191840-03657336-3CEC-43B0-A78F-9719847F35D9Q34417838-65A0BB1F-F0B2-426F-BC50-36D29C9650B2Q34772870-FE11F076-DF5E-4269-B561-F5C8D1CBFBA7Q34775968-87212FF9-AB23-4A0B-90AF-547DB9E5F00BQ35389163-6466F70A-9FC6-4ED6-B38D-E2113CD516A3Q35690302-F2168224-3FFC-4607-B2B9-9D0534A0A6F3Q35922456-8AE1F498-E6FD-4485-9387-DDC2834794B9Q35971578-C2FA9BFC-5609-4B26-8318-020B61D8A1A8Q36296251-F469F201-21BC-4A24-B5BB-A19B797A8BA5Q36379622-283F91DD-51EC-4975-8A88-5BE20ED26038Q36421892-D3EF67A4-A645-4CD2-B041-DA93FDCAA2BFQ36590774-467156C3-11B7-480B-B674-CAF7316F7C52Q36590782-50A929A7-AC8E-4C47-A352-3C7606419652Q36654120-BAF3F3CF-A1CD-4BFF-9F3E-D324D782FFA6Q36789904-8E403C50-4B5B-4CA0-A1E4-145EF7A7BED8Q36910855-B36D02EA-0C5D-46FD-945F-3126AB869C51Q37042436-5D68DA70-9DD3-4C23-849D-A827AC483121Q37055228-8AB1037B-2C61-4ADF-B191-E55AB66A3B6DQ37084628-D94C4A6C-ADA2-48B8-8162-6F981FEADB54Q37124502-880CAF53-01F3-49AB-A827-9B2DA5556AC4Q37125615-698A7D1B-A978-4DF6-AA28-F9A0D09B1804Q37151303-FCE2080C-8028-4701-A7AC-486F9E369201Q37170594-EE89A381-240A-4537-9A25-1BC7EBA21487Q37235541-B2F8D007-0C52-41D6-95A6-ACEF89116857Q37238205-5CE813C8-4887-43E7-AB6A-0F41F44DC5D3
P2860
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
@en
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
@nl
type
label
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
@en
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
@nl
prefLabel
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
@en
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
@nl
P2093
P1433
P1476
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
@en
P2093
David L Thomas
Gregory M Lucas
Lisa B Mirel
Mark S Sulkowski
Michael Torbenson
Richard D Moore
Shruti H Mehta
Yvonne Higgins
P304
P356
10.1097/QAD.0B013E32801086DA
P407
P577
2006-11-01T00:00:00Z